Rapamycin-conditioned, alloantigen-pulsed myeloid dendritic cells present donor MHC class I/peptide via the semi-direct pathway and inhibit survival of antigen-specific CD8+ T cells in vitro and in vivo

Transplant Immunology

Volumn 25, Issue 1, 2011, Pages 20-26

  Fischer, Ryan T ^a,c   Turnquist, Heth R ^a   Wang, Zhiliang ^a   Beer Stolz, Donna ^b   Thomson, Angus W ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

Author keywords

Alloantigen presentation; Apoptosis; Dendritic cells; Rapamycin; T cells

Indexed keywords

ALLOANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RAPAMYCIN;

ADOPTIVE TRANSFER; ALLOIMMUNITY; ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL LYSATE; CELL SURFACE; CELL SURVIVAL; CELL TRANSFER; CONTROLLED STUDY; IMMUNOCOMPETENT CELL; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MYELOID DENDRITIC CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ANIMALS; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOSUPPRESSIVE AGENTS; ISOANTIGENS; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MYELOID CELLS; SIROLIMUS; TRANSPLANTATION, ISOGENEIC;

EID: 79959630631     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2011.05.001     Document Type: Article

References (45)

1. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
2. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
3. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 2003, 21:685-711.
4. Lechler R.I., Batchelor J.R. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med 1982, 155:31-41.
5. Larsen C.P., Morris P.J., Austyn J.M. Migration of dendritic leukocytes from cardiac allografts into host spleens. A novel pathway for initiation of rejection. J Exp Med 1990, 171:307-314.
6. Gould D.S., Auchincloss H. Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol Today 1999, 20:77-82.
7. Benichou G., Valujskikh A., Heeger P.S. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. J Immunol 1999, 162:352-358.
8. Lechler R.I., Ng W.F., Steinman R.M. Dendritic cells in transplantation - friend or foe?. Immunity 2001, 14:357-368.
9. Morelli A.E., Thomson A.W. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007, 7:610-621.
10. Trombetta E.S., Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 2005, 23:975-1028.
11. Rogers N.J., Lechler R.I. Allorecognition. Am J Transplant 2001, 1:97-102.
12. Heath W.R., Carbone F.R. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001, 19:47-64.
13. Smyth L.A., Afzali B., Tsang J., Lombardi G., Lechler R.I. Intercellular transfer of MHC and immunological molecules: molecular mechanisms and biological significance. Am J Transplant 2007, 7:1442-1449.
14. Smyth L.A., Herrera O.B., Golshayan D., Lombardi G., Lechler R.I. A novel pathway of antigen presentation by dendritic and endothelial cells: implications for allorecognition and infectious diseases. Transplantation 2006, 82:S15-S18.
15. de Heusch M., Blocklet D., Egrise D., Hauquier B., Vermeersch M., Goldman S., et al. Bidirectional MHC molecule exchange between migratory and resident dendritic cells. J Leukoc Biol 2007, 82:861-868.
16. Dolan B.P., Gibbs K.D., Ostrand-Rosenberg S. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. J Immunol 2006, 176:1447-1455.
17. Dolan B.P., Gibbs K.D., Ostrand-Rosenberg S. Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells. J Immunol 2006, 177:6018-6024.
18. Dhodapkar M.V., Steinman R.M., Krasovsky J., Munz C., Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001, 193:233-238.
19. Nouri-Shirazi M., Thomson A.W. Dendritic cells as promoters of transplant tolerance. Expert Opin Biol Ther 2006, 6:325-339.
20. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000, 18:767-811.
21. Turnquist H., Raimondi G., Zahorchak A.F., Fischer R.T., Wang Z., Thomson A.W. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol 2007, 178:7018-7031.
22. Fazekasova H., Golshayan D., Read J., Tsallios A., Tsang J.Y., Dorling A., et al. Regulation of rat and human T-cell immune response by pharmacologically modified dendritic cells. Transplantation 2009, 87:1617-1628.
23. Kahan B.D., Camardo J.S. Rapamycin: clinical results and future opportunities. Transplantation 2001, 72:1181-1193.
24. Chueh S.C., Kahan B.D. Clinical application of sirolimus in renal transplantation: an update. Transpl Int 2005, 18:261-277.
25. Hackstein H., Taner T., Zahorchak A.F., Morelli A.E., Logar A.J., Gessner A., et al. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003, 101:4457-4463.
26. Taner T., Hackstein H., Wang Z., Morelli A.E., Thomson A.W. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce Ag-specific T cell regulation and prolong graft survival. Am J Transplant 2005, 5:228-236.
27. Thomson A.W., Turnquist H.R., Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009, 9:324-337.
28. Turnquist H.R., Thomson A.W. Taming the lions: manipulating dendritic cells for use as negative cellular vaccines in organ transplantation. Curr Opin Organ Transplant 2008, 13:350-357.
29. Turnquist H.R., Cardinal J., Macedo C., Rosborough B.R., Sumpter T.L., Geller D.A., et al. mTOR and GSK-3 shape the CD4+ T cell stimulatory and differentiation capacity of myeloid DC following exposure to LPS. Blood 2010, 115:4758-4769.
30. Monti P., Mercalli A., Leone B.E., Valerio D.C., Allavena P., Piemonti L. Rapamycin impairs antigen uptake of human dendritic cells. Transplantation 2003, 75:137-145.
31. Morelli A.E., Zahorchak A.F., Larregina A.T., Colvin B.L., Logar A.J., Takayama T., et al. Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood 2001, 98:1512-1523.
32. Hackstein H., Taner T., Logar A.J., Thomson A.W. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 2002, 100:1084-1087.
33. Ozato K., Hansen T.H., Sachs D.H. Monoclonal antibodies to mouse MHC antigens. II. Antibodies to the H-2Ld antigen, the products of a third polymorphic locus of the mouse major histocompatibility complex. J Immunol 1980, 125:2473-2477.
34. Smith J.D., Lie W.R., Gorka J., Myers N.B., Hansen T.H. Extensive peptide ligand exchange by surface class I major histocompatibility complex molecules independent of exogenous beta 2-microglobulin. Proc Natl Acad Sci U S A 1992, 89:7767-7771.
35. Galkina E., Tanousis K., Preece G., Tolaini M., Kioussis D., Florey O., et al. L-selectin shedding does not regulate constitutive T cell trafficking but controls the migration pathways of antigen-activated T lymphocytes. J Exp Med 2003, 198:1323-1335.
36. Hamann A., Klugewitz K., Austrup F., Jablonski-Westrich D. Activation induces rapid and profound alterations in the trafficking of T cells. Eur J Immunol 2000, 30:3207-3218.
37. Benichou G., Thomson A.W. Direct versus indirect allorecognition pathways: on the right track. Am J Transplant 2009, 9:655-656.
38. Herrera O.B., Golshayan D., Tibbott R., Salcido Ochoa F., James M.J., Marelli-Berg F.M., et al. A novel pathway of alloantigen presentation by dendritic cells. J Immunol 2004, 173:4828-4837.
39. Morelli A.E., Larregina A.T., Shufesky W.J., Sullivan M.L., Stolz D.B., Papworth G.D., et al. Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood 2004, 104:3257-3266.
40. Lu L., Qian S., Hershberger P.A., Rudert W.A., Lynch D.H., Thomson A.W. Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. J Immunol 1997, 158:5676-5684.
41. Horibe E.K., Sacks J., Unadkat J., Raimondi G., Wang Z., Ikeguchi R., et al. Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion. Transpl Immunol 2008, 18:307-318.
42. Ikeguchi R., Sacks J.M., Unadkat J.V., Solari M., Horibe E.K., Thomson A.W., et al. Long-term survival of limb allografts induced by pharmacologically conditioned, donor alloantigen-pulsed dendritic cells without maintenance immunosuppression. Transplantation 2008, 85:237-246.
43. Chaussabel D., Banchereau J. Dendritic cells, therapeutic vectors of immunity and tolerance. Am J Transplant 2005, 5:205-206.
44. Mirenda V., Berton I., Read J., Cook T., Smith J., Dorling A., et al. Modified dendritic cells coexpressing self and allogeneic major histocompatibility complex molecules: an efficient way to induce indirect pathway regulation. J Am Soc Nephrol 2004, 15:987-997.
45. McCurry K.R., Colvin B.L., Zahorchak A.F., Thomson A.W. Regulatory dendritic cell therapy in organ transplantation. Transpl Int 2006, 19:525-538.